Vironova Medical strives to protect all technology and products developed. Patent applications are submitted in all relevant markets for both our chemical process technology and our drug development candidates. Currently Vironova Medical has five different patent families including both active patents and patent applications.
Founded in 2015 as a spin-out from Vironova AB, Vironova Medical AB is developing antiviral compounds against herpes and influenza virus. In our portfolio we have patented antiviral molecules with a novel mode of action. In addition, we also have a chemical process technology for thionation of compounds used in pharmaceuticals. Thionating drug molecules can alter characteristics such as bioavailability and result in more potent and selective compounds.
Board of directors Vironova Medical AB
Mr. Homman has a M.Sc. in Chemistry and B.Sc in biology from Uppsala University in 1998. Mohammed has been the driving force behind the development of the virus analysis technique and VN-180. Mohammed has received several national and international awards in recognition of his entrepreneurship and innovative research achievements. In 2003 Mohammed was chosen as one of the “Leaders of Tomorrow” by the Academy of Achievement, USA.
Professor in anesthesiology and intensive care since 1999 at the Department of Clinical Science, Intervention and Technology at the Karolinska Institute. Dr. Sollevi received his medical degree in 1976 and became a licensed physician in 1978. He received his PhD in 1981. After two years as Associate Professor of Pharmacology, he became a docent in anesthesiology and intensive care in 1986. During a long period, from 1982 to 2008, has Dr. Sollevi lead a research group that conducted basic studies as well as clinical examinations regarding effects and clinical applicability of the endogenous substance adenosine.
Maria Homman holds a PhD in polymer technology and has been a manager within R&D at AkzoNobel (initially Casco Adhesives) for 10 years, with responsibility for the development of products from idea to market, as well as customer support. Dr. Maria Homman is currently the COO of Vironova.
M.Sc. from Stockholm School of Economics. Ulf has 25 years of experience in the pharmaceutical industry, mostly in international and global roles. Most recently 10 years as President Europe in AstraZeneca, based in Brussels, followed by the role as Global Marketing Director at the company headquarters in London. Earlier in his career he also held sales and marketing roles in the US. Board member in RISE (Research Institutes of Sweden), a government body with 2500 employees doing front line research in collaboration with industry, N-side, Leuwen Belgium, a consulting firm in mathematical analysis, Nobelux, a trade org to support trade between Sweden and Belux. Former member of the board at AB Blåklader (working wear) and Chairman in the AZ Germany Supervisory Board. Industrial Advisor at EQT.
M.Sc. from Stockholm School of Economics, MBA from University of Berkeley, California. Mats Persson has extensive experience as CEO at several Swedish companies including AGA Gas, Thermiaverken, Candor and Interspiro, with a focus on implementing major organizational changes and increasing profitability. During 1996-2012 Mats Persson served as main shareholder in Neuman and Nydahl, offering qualified counselling, leadership development and recruitment at managerial level to leading companies in Sweden, including Incentive, Skanska, Swedbank, Boliden, Loomis, Nynäs and Pharmacia. Mats Persson has over 20 years of experience in board work, and is currently board member at Prolight Diagnostics, Newfour, QBNK (Aktietorget) and Vironova.
The Vironova Medical Group consists of four companies:
Vironova Medical AB is the mother company.
Vironova Thionation AB, the vehicle for the Thionation project, is a partly owned subsidiary to Vironova Medical as well as Vironova Influenza AB and Vironova Herpes AB.
Vironova Medical´s patent strategy
Vironova Thionation AB has submitted a patent for a new chemical synthetic method – thionation. The thionation process patent is so far approved in EPC and the thionation reagent patent is granted in U.S. Several patent applications are still pending in the national stage. By applying the thionation method on antiviral substances against influenza, new drug candidates have been synthesized with patents submitted and approved. These patents belong to Vironova Influenza AB.
The pharmaceutical candidates against herpes are protected by a patent family that includes all eight human herpes viruses. The patent for the pharmaceutical formulation for topical administration against herpes virus comprising of the B-220 compound has so far been granted in Australia, while other patent applications worldwide are pending. In U.S. granted claims protecting the method of treating a herpes virus infection with a B-220 pharmaceutical formulation has been approved. All anti-herpes patents belong to Vironova Herpes AB.